Download
blood preparation market is estimated to reach n.
Skip this Video
Loading SlideShow in 5 Seconds..
Blood Preparation Market Is Estimated To Reach USD 58.69 Billion By 2022 PowerPoint Presentation
Download Presentation
Blood Preparation Market Is Estimated To Reach USD 58.69 Billion By 2022

Blood Preparation Market Is Estimated To Reach USD 58.69 Billion By 2022

25 Views Download Presentation
Download Presentation

Blood Preparation Market Is Estimated To Reach USD 58.69 Billion By 2022

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Blood Preparation Market Is Estimated To Reach USD 58.69 Billion By 2022 “Growing worldwide demand for transfusion of blood and its components and increasing prevalence of blood-related disorders are expected to fuel the growth of the blood preparation market over the forecast period.” The Global Blood Preparation Market is expected to reach USD 58.69 billion by 2022, according to a new study by Grand View Research, Inc. Growing worldwide demand for transfusion of blood and its components and increasing prevalence of blood-related disorders are expected to fuel the growth of the blood preparation market over the forecast period. The worldwide prevalence of thrombocytosis-associated disorders is steeply increasing. According to the Center for Disease control and Prevention (CDC), one to two people per 1,000 are affected by DVT/PE in the U.S. each year, and 60,000- 100,000 Americans die due to DVT/PE. Commercialization of drugs currently in the pipeline, introduction of new oral anticoagulants, and the presence of large untapped opportunities are expected to boost product demand by triggering the incidence rates of target diseases. Access Full Research Report on Global Blood Preparation Market: http://www.grandviewresearch.com/industry-analysis/blood-preparation-market Follow Us:

  2. Anticoagulants was the largest product segment in 2014 owing to, the increasing R&D aimed at the the development of novel prophylactic and therapeutic drugs. Re-launch of some key drug products such as Urokinase in North America is most likely expected to boost market growth over the forecast period. Microbix Biosystems Inc. acquired Urokinase from Abbott Laboratories (Abbokinase) to relaunch it as Kinelytic in the U.S. The drug is under regulatory approval and is expected to be relaunched in the middle of 2015 in the U.S. Further key findings from the study suggest: The blood derivates market was valued at over 13.0 billion in 2014 and is expected grow at a lucrative rate from 2015 to 2022 owing to, the increasing transfusion needs of blood and its components. Increasing number of R&D pertaining to the development of blood-derived medicines and expected commercialization of new drugs are also expected to serve as high impact rendering drivers. The direct factor Xa inhibitors market is identified as the most lucrative segment on account of the introduction of new oral products such as Xarelto, Savaysa, and Eliquis, targeting unmet medical needs. The North American blood preparation market was the largest in 2014. The presence of sophisticated healthcare infrastructure and high patient awareness levels coupled with relatively higher healthcare expenditure levels in the region are some factors attributing to its market position. Asia Pacific is anticipated to witness high future growth over the forecast period, owing to the presence of favorable government initiatives, sophisticated healthcare infrastructure in Japan and Australia and large untapped opportunities in the emerging markets of China and India. Key players of the blood preparation market include GlaxoSmithKline PLC, Pfizer Inc., Baxter Healthcare Corp., Bristol-Myers Squibb Co., Leo Pharma Inc., Sanofi Aventis, AstraZeneca Co., and Celgene Corp. Follow Us:

  3. Grand View Research has segmented the global Blood Preparation Market on the basis of products, anti-thrombotics and anticoagulant type, anti-thrombotics and anticoagulant application, and region: Read Our Blogs on Reports from this category By Grand View Research: http://www.grandviewresearch.com/blogs/healthcare Table of Content of Global Blood Preparation Market Research Report: Chapter 1 Methodology and Scope 1.1 Research Methodology 1.2 Research Scope & Assumptions 1.3 List of Data Sources Chapter 2 Executive Summary 2.1 Blood Preparation Market - Industry Snapshot & Key Buying Criteria, 2012 - 2022 Chapter 3 Blood Preparation Industry Outlook 3.1 Market segmentation 3.2 Market size and growth prospects 3.3 Blood preparation: Market dynamics 3.3.1 Market driver analysis 3.3.1.1 Growing demand for whole blood and blood components transfusion 3.3.1.2 Increasing usage of plasma in pharmaceutical industry 3.3.1.3 Increasing Geriatric population 3.3.1.4 Presence of a strong product pipeline portfolio 3.3.1.5 Presence of advanced technology for blood preparation and storage 3.3.2 Market restraint analysis 3.3.2.1 Risk of blood transmitted diseases and growing blood Follow Us:

  4. subsitutes 3.4 Key Opportunities Prioritized 3.5 Industry analysis - Porter’s 3.6 Blood preparation - PESTEL Analysis 3.7 Government Initiatives and Trends 3.8 Blood Preparation - Pipeline and New Product Development Analysis Chapter 4 Blood Preparation Product Outlook 4.1 Blood preparation market share by product, 2014 & 2022 4.2 Whole blood market 4.2.1 Whole blood market, 2012 - 2022 (USD Million) 4.2.2 Red cells 4.2.2.1 Red cells market, 2012 - 2022 (USD Million) 4.2.3 Granulocytes 4.2.3.1 Granulocytes market, 2012 - 2022 (USD Million) 4.2.4 Plasma 4.2.4.1 Plasma market, 2012 - 2022 (USD Million) 4.2.5 Platelets 4.2.5.1 Platelets market, 2012 - 2022 (USD Million) 4.3 Blood components market 4.3.1 Blood components market, 2012 - 2022 (USD Million) 4.3.2 Whole blood components market, 2012 - 2022 (USD Million) 4.3.3 Packed red cells 4.3.3.1 Packed red cells market, 2012 - 2022 (USD Million) 4.3.4 Leukocyte reduced red blood cells 4.3.4.1 Leukocyte reduced red blood cells market, 2012 - 2022 (USD Million) 4.3.5 Frozen plasma Follow Us:

  5. 4.3.5.1 Frozen plasma market, 2012 - 2022 (USD Million) 4.3.6 Platelet concentrate 4.3.6.1 Platelet concentrate market, 2012 - 2022 (USD Million) 4.3.7 Cryoprecipitate 4.3.7.1 Cryoprecipitate market, 2012 - 2022 (USD Million) 4.4 Blood derivatives 4.4.1 Blood derivatives market, 2012 - 2022 (USD Million) Chapter 5 Anti-thrombotic And Anticoagulants Type Outlook 5.1 Anti-thrombotic and anticoagulants market share by type, 2014 & 2022 5.2 Platelet Aggregation Inhibitors market 5.2.1 Platelet aggregation inhibitors market, 2012 - 2022 (USD Million) 5.2.2 Glycoprotein inhibitors 5.2.2.1 Glycoprotein inhibitors market, 2012 - 2022 (USD Million) 5.2.3 COX inhibitors 5.2.3.1 COX inhibitors market, 2012 - 2022 (USD Million) 5.2.4 ADP antagonists 5.2.4.1 ADP antagonists market, 2012 - 2022 (USD Million) 5.2.5 Phosphodiesterase inhibitors 5.2.5.1 Phosphodiesterase inhibitors market, 2012 - 2022 (USD Million) 5.2.6 Others market, 2012 - 2022 (USD Million) 5.3 Fibrinolytics market 5.3.1 Fibrinolytics market, 2012 - 2022 (USD Million) 5.3.2 Tissue Plasminogen Activator (tPA) 5.3.2.1 Tissue Plasminogen Activator (tPA) market, 2012 - 2022 (USD Million) 5.3.3 Streptokinase Follow Us:

  6. 5.3.3.1 Streptokinase market, 2012 - 2022 (USD Million) 5.3.4 Urokinase 5.3.4.1 Urokinase market, 2012 - 2022 (USD Million) 5.4 Anticoagulants 5.4.1 Anticoagulants market, 2012 - 2022 (USD Million) 5.4.2 Heparins 5.4.2.1 Heparins market, 2012 - 2022 (USD Million) 5.4.2.2 Unfractionated heparin market, 2012 - 2022 (USD Million) 5.4.2.3 Low Molecular Weight Heparin (LMWH) market, 2012 - 2022 (USD Million) 5.4.2.4 Ultra-low Molecular Weight Heparin(ULMWH) market, 2012 - 2022 (USD Million) 5.4.3 Vitamin K antagonists 5.4.3.1 Vitamin K antagonists market, 2012 - 2022 (USD Million) 5.4.4 Direct thrombin inhibitors 5.4.4.1 Direct thrombin inhibitors market, 2012 - 2022 (USD Million) 5.4.5 Direct factor Xa inhibitors 5.4.5.1 Direct factor Xa inhibitors market, 2012 - 2022 (USD Million) Chapter 6 Anti-thrombotic And Anticoagulants Application Outlook 6.1 Anti-thrombotic and anticoagulants market share by application, 2014 & 2022 6.2 Thrombocytosis 6.2.1 Thrombocytosis market, 2012 - 2022 (USD Million) 6.3 Pulmonary embolism 6.3.1 Pulmonary embolism market, 2012 - 2022 (USD Million) 6.4 Renal impairment 6.4.1 Renal impairment market, 2012 - 2022 (USD Million) Follow Us:

  7. 6.5 Angina blood vessel complications 6.5.1 Angina blood vessel complications market, 2012 - 2022 (USD Million) 6.6 Others 6.6.1 Others market, 2012 - 2022 (USD Million) Chapter 7 Blood preparation Regional Outlook 7.1 Blood preparation market share, by region, 2014 & 2022 7.2 North America 7.2.1 North America Blood preparation market, 2012 - 2022 (USD Million) 7.2.2 U.S. 7.2.2.1 U.S. market, by product, 2012 - 2022 (USD Million) 7.2.4 Canada 7.2.4.1 Canada market, by product, 2012 - 2022 (USD Million) 7.3 Europe 7.3.1 Europe blood preparation market, 2012 - 2022 (USD Million) 7.3.2 Germany 7.3.2.1 Germany market, by product, 2012 - 2022 (USD Million) 7.3.4 France 7.3.4.1 France market, by product, 2012 - 2022 (USD Million) 7.3.6 UK 7.3.6.1 UK market, by product, 2012 - 2022 (USD Million) 7.3.8 Italy 7.3.8.1 Italy market, by product, 2012 - 2022 (USD Million) 7.4 Asia Pacific 7.4.1 Asia Pacific blood preparation market, 2012 - 2022 (USD Million) 7.4.2 Japan 7.4.2.1 Japan market, by product, 2012 - 2022 (USD Million) Follow Us:

  8. 7.4.4 China 7.4.4.1 China market, by product, 2012 - 2022 (USD Million) 7.5 Latin America 7.5.1 Latin America blood preparation market, 2012 - 2022 (USD Million) 7.5.2 Brazil 7.5.2.1 Brazil market, by product, 2012 - 2022 (USD Million) 7.5.4 Mexico 7.5.4.1 Mexico market, by product, 2012 - 2022 (USD Million) 7.6 MEA 7.6.1 MEA blood preparation market, 2012 - 2022 (USD Million) 7.6.2 South Africa 7.6.2.1 South Africa market, by product, 2012 - 2022 (USD Million) Chapter 8 Anti-thrombotic And Anticoagulants Regional Outlook 8.1 Anti-thrombotic and anticoagulants market share, by region, 2014 & 2022 8.2 North America anti-thrombotic and anticoagulants market, 2012 - 2022 (USD Million) 8.2.1 U.S. anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.2.2 Canada anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.3 Europe anti-thrombotic and anticoagulants market, 2012 - 2022 (USD Million) 8.3.1 Germany anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.3.2 France anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) Follow Us:

  9. 8.3.3 UK anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.3.4 Italy anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.4 Asia Pacific anti-thrombotic and anticoagulants market, 2012 - 2022 (USD Million) 8.4.1 Japan anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.4.2 China anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.5 Latin America anti-thrombotic and anticoagulants market, 2012 - 2022 (USD Million) 8.5.1 Brazil anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.5.2 Mexico anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) 8.6 MEA anti-thrombotic and anticoagulants market, 2012 - 2022 (USD Million) 8.6.1 South Africa anti-thrombotic and anticoagulants market, by product, 2012 - 2022 (USD Million) Chapter 9 Competitive Landscape 9.1 GlaxoSmithKline PLC 9.1.1 Company Overview 9.1.2 Financial Performance 9.1.3 Product Benchmarking 9.1.4 Strategic Initiatives 9.2 Pfizer Inc. Follow Us:

  10. 9.2.1 Company Overview 9.2.2 Financial Performance 9.2.3 Product Benchmarking 9.2.4 Strategic Initiatives 9.3 Baxter Healthcare Corp. 9.3.1 Company Overview 9.3.2 Financial Performance 9.3.3 Product Benchmarking 9.3.4 Strategic Initiatives 9.4 Shandong East Chemical Industry Co. 9.4.1 Company Overview 9.4.2 Financial Performance 9.4.3 Product Benchmarking 9.5 Bristol-Myers Squibb Co. 9.5.1 Company Overview 9.5.2 Financial Performance 9.5.3 Product Benchmarking 9.5.4 Strategic Initiatives 9.6 Leo Pharma Inc. 9.6.1 Company Overview 9.6.2 Financial Performance 9.6.3 Product Benchmarking 9.6.4 Strategic Initiatives 9.7 Sanofi Aventis 9.7.1 Company Overview 9.7.2 Financial Performance 9.7.3 Product Benchmarking Follow Us:

  11. 9.7.4 Strategic Initiatives 9.8 Hisunny Chemical Co 9.8.1 Company Overview 9.8.2 Financial Performance 9.8.3 Product Benchmarking 9.9 AstraZeneca Co 9.9.1 Company Overview 9.9.2 Financial Performance 9.9.3 Product Benchmarking 9.9.4 Strategic Initiatives 9.10 Celgene Corp. 9.10.1 Company Overview 9.10.2 Financial Performance 9.10.3 Product Benchmarking 9.10.4 Strategic Initiatives About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Follow Us:

  12. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email:sales@grandviewresearch.com For More Information:http://www.grandviewresearch.com Follow Us: